Study guide

6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics

2 Chapter 2: Transport and Safety (Part 1)

2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols

3 Chapter 2: Transport and Safety (Part 2)

2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations

4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)

3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes

5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)

3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation

6 Chapter 4: General Medical Patient

4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport

7 Chapter 5: Cardiac Patient

5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care

8 Chapter 6: Neurological Patient

6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

9 Chapter 7: Respiratory Patient

7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds

10 Chapter 8: Toxic Exposure and Environmental Patient

8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat

11 Chapter 9: Trauma and Burn Patient

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome

12 Chapter 10: Maternal and Fetal Medicine

10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring

13 Chapter 11: Pediatric Patient

11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate

14 Chapter 12: Special Populations

12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology

15 Chapter 13: Professional Considerations

13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice

6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

Key Takeaways Explain This Topic AI

Status epilepticus is defined as ≥ 5 minutes \ge 5 \text{ minutes} ≥ 5 minutes of continuous seizure activity or ≥ 2 \ge 2 ≥ 2 discrete seizures without complete neurological recovery in between.

Status epilepticus pharmacotherapy escalates from first-line benzodiazepines (Lorazepam 4 mg 4 \text{ mg} 4 mg IV, Midazolam 10 mg 10 \text{ mg} 10 mg IM) to second-line non-sedating AEDs (Levetiracetam 60 mg/kg 60 \text{ mg/kg} 60 mg/kg , Fosphenytoin 20 mg PE/kg 20 \text{ mg PE/kg} 20 mg PE/kg , Valproate 40 mg/kg 40 \text{ mg/kg} 40 mg/kg ).

Third-line refractory status epilepticus requires continuous anesthetic infusions (Propofol, Ketamine, Pentobarbital) with endotracheal intubation and EEG monitoring.

Neurogenic shock (loss of sympathetic tone below T6) presents with severe hypotension, profound bradycardia, and warm dry skin; spinal shock is a transient neurological state of motor/reflex loss.

Neurogenic shock hemodynamics demand maintaining a MAP target of 85 − 90 mmHg 85-90 \text{ mmHg} 85 − 90 mmHg for at least 7 days using Norepinephrine or Dopamine to preserve spinal cord perfusion.

Last updated: July 2026

6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

Neurological emergencies involving ongoing seizure activity or acute traumatic spinal cord injury require rapid algorithmic intervention. Uncontrolled status epilepticus causes irreversible neuronal destruction, systemic acidosis, and hyperthermia. High spinal cord injuries disrupt sympathetic output, producing neurogenic shock that severely compromises spinal cord perfusion. Critical Care Paramedics must execute tiered antiepileptic protocols and maintain strict hemodynamic goals to optimize patient survival and functional recovery.

Status Epilepticus: Definition & Operational Timelines

Historically defined as 30 minutes of continuous seizure activity, operational guidelines now establish T 1 T_1 T 1 ​ (5 minutes) as the point at which seizure activity is unlikely to self-terminate and emergency pharmacotherapy must begin.

Operational Definitions

Status Epilepticus (SE) : Continuous seizure activity lasting ≥ 5 minutes \ge 5 \text{ minutes} ≥ 5 minutes , or ≥ 2 \ge 2 ≥ 2 discrete seizure episodes between which the patient does not regain baseline consciousness.

Refractory Status Epilepticus (RSE) : Seizure activity that persists despite adequate doses of a first-line benzodiazepine and a second-line antiepileptic drug (AED).

Super-Refractory Status Epilepticus (SRSE) : Seizure activity that continues or recur 24 hours or more after initiation of continuous anesthetic infusions, or recurs upon weaning anesthetics.

Tiered Pharmacotherapy Escalation for Status Epilepticus

Pharmacological management proceeds in rapid sequential steps to abort seizure activity and prevent excitotoxic brain injury.

Treatment Phase Pharmacological Agents Recommended Dosing & Administration

Phase 1: Emergent Therapy ; (0 – 5 to 10 min) 1st Line: Benzodiazepines ; • Lorazepam (Ativan); • Midazolam (Versed); • Diazepam (Valium) • Lorazepam : 4 mg 4 \text{ mg} 4 mg IV push over 2 min (or 0.1 mg/kg 0.1 \text{ mg/kg} 0.1 mg/kg IV). Preferred IV agent.; • Midazolam : 10 mg 10 \text{ mg} 10 mg IM (if no IV access; or 0.2 mg/kg 0.2 \text{ mg/kg} 0.2 mg/kg IM, max 10 mg 10 \text{ mg} 10 mg ).; • Diazepam : 10 mg 10 \text{ mg} 10 mg IV push ( 0.2 mg/kg 0.2 \text{ mg/kg} 0.2 mg/kg ). High lipophilicity results in rapid CNS redistribution.

Phase 2: Urgent Control ; (10 to 20 to 40 min) 2nd Line: Non-sedating AEDs ; • Levetiracetam (Keppra); • Fosphenytoin (Cerebyx); • Valproate Sodium (Depacon) • Levetiracetam : 60 mg/kg 60 \text{ mg/kg} 60 mg/kg IV (max 4500 mg 4500 \text{ mg} 4500 mg ) over 10–15 min.; • Fosphenytoin : 20 mg PE/kg 20 \text{ mg PE/kg} 20 mg PE/kg IV (max 1500 mg PE 1500 \text{ mg PE} 1500 mg PE ) at max 150 mg PE/min 150 \text{ mg PE/min} 150 mg PE/min .; • Valproate Sodium : 40 mg/kg 40 \text{ mg/kg} 40 mg/kg IV (max 3000 mg 3000 \text{ mg} 3000 mg ) over 5–10 min.

Phase 3: Refractory SE ; (> 40 min) 3rd Line: Anesthetic Infusions ; • Propofol (Diprivan); • Ketamine; • Pentobarbital • Propofol : Load 1 − 2 mg/kg 1-2 \text{ mg/kg} 1 − 2 mg/kg IV, continuous infusion 2 − 10 mg/kg/hr 2-10 \text{ mg/kg/hr} 2 − 10 mg/kg/hr ( 30 − 150 μ g/kg/min 30-150 \ \mu\text{g/kg/min} 30 − 150 μ g/kg/min ).; • Ketamine : Load 1.5 − 4.5 mg/kg 1.5-4.5 \text{ mg/kg} 1.5 − 4.5 mg/kg IV, continuous infusion 1 − 5 mg/kg/hr 1-5 \text{ mg/kg/hr} 1 − 5 mg/kg/hr .; • Pentobarbital : Load 5 mg/kg 5 \text{ mg/kg} 5 mg/kg IV, infusion 1 − 5 mg/kg/hr 1-5 \text{ mg/kg/hr} 1 − 5 mg/kg/hr titrated to burst suppression.

Critical AED Dosing Considerations

Fosphenytoin vs. Phenytoin : Fosphenytoin is a water-soluble prodrug measured in Phenytoin Equivalents (PE). Unlike legacy IV Phenytoin, Fosphenytoin does not contain propylene glycol, eliminating the risks of severe hypotension, cardiac dysrhythmias, and purple glove syndrome (tissue necrosis from extravasation).

Refractory Airway & EEG : Any patient requiring Phase 3 continuous anesthetic infusions must undergo endotracheal intubation, mechanical ventilation, invasive arterial pressure monitoring, and continuous electroencephalography (cEEG) to titrate infusions to electrographic seizure termination or burst suppression.

Acute Spinal Cord Injury (SCI) & Neurogenic vs. Spinal Shock

Traumatic injury to the spinal cord produces two distinct syndromes that are frequently confused: Spinal Shock (a neurological state) and Neurogenic Shock (a hemodynamic state).

Differentiating Spinal Shock and Neurogenic Shock

  • Diagnostic Feature Spinal Shock Neurogenic Shock
  • Underlying Nature Neurological Recovery Condition Hemodynamic Distributive Shock

Pathophysiology Sudden transient cessation of all spinal cord electrical activity and reflex arcs below the level of injury. Loss of sympathetic vascular tone and cardiac sympathetic innervation due to cord lesion at or above T6 .

Clinical Manifestations • Flaccid paralysis; • Complete loss of deep tendon reflexes; • Absence of bulbocavernosus reflex; • Loss of somatic sensation • Severe Hypotension (massive arterial/venous vasodilation); • Profound Bradycardia (unopposed vagal tone); • Warm, Dry Skin & Poikilothermia

Duration Hours to weeks (resolves as spinal reflexes return, progressing to spasticity). Days to several weeks (requires active vasoactive support).

Neurogenic Shock Pathophysiology & Presentation

Neurogenic shock occurs following severe cervical or high-thoracic spinal cord injuries ( T6 and above ). Sympathetic preganglionic neurons originate in the thoracolumbar spinal cord ( T 1 − L 2 T1 - L2 T 1 − L 2 ).

Mechanisms of Clinical Triad

Severe Hypotension : Disruption of descending sympathetic pathways abolishes vascular tone, resulting in profound vasodilation, venous pooling in lower extremities, decreased venous return (preload), and reduced cardiac output.

Profound Bradycardia : Sympathetic innervation to the heart originates from the T 1 − T 4 T1 - T4 T 1 − T 4 cardiac accelerator fibers . Injuries above T4 block cardiac sympathetic stimulation, leaving parasympathetic (vagal) innervation completely unopposed.

Warm, Dry Skin : Loss of sympathetic control stops peripheral vasoconstriction and sweating below the injury level, causing peripheral blood pooling and skin warmth.

Hemodynamic Management in Neurogenic Shock

Secondary ischemia of the injured spinal cord exacerbates permanent neurological deficits. Maintaining spinal cord blood flow requires strict arterial pressure targets.

Mean Arterial Pressure Target

MAP Target : Maintain MAP between 85 − 90 mmHg 85 - 90 \text{ mmHg} 85 − 90 mmHg for at least 7 days following acute spinal cord injury.

Clinical Purpose : Elevating MAP drives perfusion through damaged, auto-regulated spinal cord microvasculature, preserving marginal motor/sensory pathways.

Fluid Resuscitation & Vasopressor Protocol Resuscitation Sequence = Judicious Isotonic Crystalloid ⟶ Ino-Vasopressor Infusion (Norepinephrine) \text{Resuscitation Sequence} = \text{Judicious Isotonic Crystalloid} \longrightarrow \text{Ino-Vasopressor Infusion (Norepinephrine)} Resuscitation Sequence = Judicious Isotonic Crystalloid ⟶ Ino-Vasopressor Infusion (Norepinephrine)

Judicious Fluid Resuscitation : Administer small crystalloid boluses ( 500 − 1000 mL 500 - 1000 \text{ mL} 500 − 1000 mL 0.9 % 0.9\% 0.9% NS or LR) to correct hypovolemia. Avoid excessive volume resuscitation; excess fluid in the setting of lost vascular tone leads to acute pulmonary edema.

First-Line Vasopressor — Norepinephrine : Norepinephrine is the primary vasopressor of choice. Its strong α 1 \alpha_1 α 1 ​ -adrenergic agonist activity restores systemic vascular resistance (SVR) and arterial vasoconstriction, while its β 1 \beta_1 β 1 ​ -agonist activity provides chronotropic and inotropic support to overcome bradycardia.

Second-Line / Alternative Vasopressor — Dopamine : Dopamine infusion ( 5 − 15 μ g/kg/min 5 - 15 \ \mu\text{g/kg/min} 5 − 15 μ g/kg/min ) provides dual α 1 \alpha_1 α 1 ​ and β 1 \beta_1 β 1 ​ stimulation. However, dopamine carries a significantly higher incidence of tachydysrhythmias compared to norepinephrine.

Phenylephrine Caution : Phenylephrine is a pure α 1 \alpha_1 α 1 ​ agonist. While it increases SVR, it produces reflex bradycardia , which dangerously worsens the profound bradycardia already present in high SCI/neurogenic shock. Phenylephrine should be avoided unless severe tachycardia is present or co-administered with chronotropic agents.